Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential CHOP followed by mogamulizumab for untreated primary adult T-cell leukemia-lymphoma
jRCTs071180057Completed
- Sponsor
- Kyowa Kirin
- Start
- Oct 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of mogamulizumab, cyclophosphamide, doxorubicin, vincristine and prednisone in adult T-cell leukemia-lymphoma (ATLL), sponsored by Kyowa Kirin. Primary endpoint: Overall survival. Started Oct 2016; status: completed.
02
Drugs
mogamulizumabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on jRCTs071180057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180057.